Michael Rupp, MD
Allergy & Immunology · Las Cruces, NMNPI 1568414985
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,800 of the $40,613 with a category attached, or 83.2%. AstraZeneca accounts for 88.9% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $36,701, more than ten times the $511 reported in 2019.
Across 282 payments — averaging $144.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$36K
- GSK$1K
- CSL Behring$667
- Regeneron Healthcare Solutions, Inc.$305
- ARS Pharmaceuticals Operations, Inc.$263
- Sanofi$248
- plus $2K from 21 others
What the payments were for
- Consulting fees$900%
- Speaking & faculty fees$33,80083%
- Travel & lodging$8852%
- Food & beverage$5,67414%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $36,096 |
| GSK | 50 | $1,311 |
| CSL Behring | 38 | $667 |
| Regeneron Healthcare Solutions, Inc. | 14 | $305 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $263 |
| Sanofi | 14 | $248 |
| Grifols USA, LLC | 13 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $213 |
| Pfizer | 22 | $174 |
| Amgen(2 entities) | 2 | $158 |
| Novartis | 8 | $138 |
| Alk-abello, Inc | 1 | $123 |
| Incyte Corporation | 4 | $123 |
| Optinose US, Inc. | 8 | $117 |
| Blueprint Medicines Corporation | 5 | $96 |
| Pharming Healthcare, Inc. | 2 | $83 |
| Boehringer Ingelheim | 4 | $76 |
| Verona Pharma, Inc. | 2 | $38 |
| Viatris Specialty LLC | 1 | $29 |
| Genentech USA, Inc. | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Biocryst US Sales Co., LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Merck | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| ADMA Biomanufacturing LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 169 | $152,944 |
| XolairOmalizumab | 25 | $134,700 |
| HyqviaIgg/Hyaluronidase,recombinant | 16 | $95,813 |
| NucalaMepolizumab | 13 | $55,697 |
| Dupixent PenDupilumab | 13 | $49,857 |
| TezspireTezepelumab-Ekko | 11 | $45,665 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $37,230 |
| Arnuity ElliptaFluticasone Furoate | 88 | $32,638 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $32,192 |
| Azelastine Hcl | 775 | $31,439 |
| Spiriva RespimatTiotropium Bromide | 28 | $23,381 |
| Ipratropium Bromide | 265 | $20,999 |
| Spiriva HandihalerTiotropium Bromide | 13 | $13,558 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $12,700 |
| Qvar RedihalerBeclomethasone Dipropionate | 22 | $10,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $1,311 | $278,510329 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $213 | $95,81316 claims |
| AstraZenecaTezspire, Symbicort | $36,096 | $77,85776 claims |
| Boehringer IngelheimSpiriva Respimat | $76 | $23,38128 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl | $14 | $14,82133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Las Cruces
- Todd FunkhouserLas Cruces$7K
- Stanislaus TingLas Cruces$1K
- Amanda Grippen GoddardAlbuquerque$14K
- Jack GhablyAlbuquerque$14K
- Shanze WangAlbuquerque$12K
- Osman DokmeciAlbuquerque$12K
- Corey ClaySanta Fe$11K
- Teresa Jenkins-MccordAlbuquerque$10K
- James SussmanSanta Fe$9K
- Janna TuckSanta Fe$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.